Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cellectis SA

CLLS
Current price
2.87 USD -0.14 USD (-4.65%)
Last closed 3.04 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 217 614 752 USD
Yield for 12 month +28.70 %
Week
Month
Year
CLLS
21.11.2021 - 28.11.2021

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Address: 8, rue de la Croix Jarry, Paris, France, 75013

Analytics

WallStreet Target Price

7.25 USD

P/E ratio

Dividend Yield

Current Year

+19 171 000 USD

Last Year

+73 949 000 USD

Current Quarter

+155 000 USD

Last Quarter

+178 000 USD

Current Year

+17 399 000 USD

Last Year

+37 674 000 USD

Current Quarter

-26 000 USD

Last Quarter

+123 000 USD

Key Figures CLLS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -64 684 000 USD
Operating Margin TTM -1257.3 %
PE Ratio
Return On Assets TTM -18.78 %
PEG Ratio
Return On Equity TTM -71.28 %
Wall Street Target Price 7.25 USD
Revenue TTM 24 525 000 USD
Book Value 1.37 USD
Revenue Per Share TTM 0.47 USD
Dividend Share
Quarterly Revenue Growth YOY -12.5 %
Dividend Yield
Gross Profit TTM 23 952 000 USD
Earnings Share -1.41 USD
Diluted Eps TTM -1.41 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CLLS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CLLS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CLLS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 13.5592
Price Sales TTM 8.8732
Enterprise Value EBITDA -4.0076
Price Book MRQ 2.8681

Financials CLLS

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators CLLS

For 52 weeks

0.96 USD 4.04 USD
50 Day MA 1.98 USD
Shares Short Prior Month 362 521
200 Day MA 1.98 USD
Short Ratio 0.29
Shares Short 1 455 019
Short Percent 4.09 %